Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Dow Jones Top Company Headlines at 7 PM ET: JPMorgan Stock Sinks on Higher Expense Outlook. Other Banks May Have to Keep Up. | Nvidia ... JPMorgan Stock Sinks on Higher Expense Outlook. Other Banks ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...

Dec 9 (Reuters) - Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Eli Lilly announced plans to construct a $6 billion pharmaceutical manufacturing facility in Huntsville, aiming to enhance ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Welcome The Hill’s annual list of Top Lobbyists. President Trump’s return to the White House brought a whirlwind of policy ...

Eli Lilly and Company announced it will invest more than $6 billion to build a major pharmaceutical manufacturing facility on ...